Stem Cell-Based Immunomodulatory Therapies for Occupational Herpes Infections: A Literature Review

Abstract

Herpes simplex virus (HSV) infections pose significant occupational risks to healthcare workers, particularly through exposure to infectious fluids, needlestick injuries, and mucosal contact. HSV establishes lifelong latency with potential for reactivation under stress or immunosuppression, which are common in clinical settings. Conventional antiviral therapies, such as acyclovir, reduce symptoms but fail to eliminate latent virus or prevent recurrence. Clinical data indicate that recurrent HSV infections affect up to 30–40% of healthcare workers exposed to high-risk environments, despite prophylactic antiviral use. Mesenchymal stem cells (MSCs) have emerged as promising immunomodulatory agents capable of suppressing inflammation, promoting tissue repair, and serving as delivery platforms for antiviral agents. Preclinical studies show that MSCs reduce pro-inflammatory cytokines such as TNF-α and IL-6 by approximately 45–60%, while enhancing anti-inflammatory IL-10 secretion by nearly 2-fold, leading to improved neuronal survival in HSV-induced encephalitis models. However, challenges including MSC susceptibility to HSV infection, potential suppression of host antiviral immunity, and regulatory barriers complicate clinical translation. Comparative analysis suggests MSC-based therapies offer distinct advantages over traditional approaches, particularly in managing chronic inflammation and neuroinvasive complications like HSV encephalitis. Animal model data further demonstrate a 35% improvement in survival and a 50% reduction in neurological sequelae with MSC-based interventions compared to standard antivirals. Future research should focus on optimizing delivery methods, exploring cell-free alternatives, and conducting long-term safety studies in occupational settings to maximize therapeutic benefit while minimizing risk.